Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 6.66% is 64% below its 5-year average of 18.70%, near the low end of its 5-year range (0.49%–108.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.61% below its 12-month average of 8.38%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 6.66%.
DEBT TO ASSETS RATIO
6.66%
DEBT TO ASSETS RATIO AVG TTM
8.38%
DEBT TO ASSETS RATIO AVG 3Y
8.02%
DEBT TO ASSETS RATIO AVG 5Y
18.70%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-20.61%
CURRENT VS 3Y AVG
-17.05%
CURRENT VS 5Y AVG
-64.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+7295.78%
vs the sector median at left
Ensysce Biosciences, Inc.
Market Cap
$6.72M
Debt to Assets Ratio
6.66%
TTM Avg
8.38%
3Y Avg
8.02%
5Y Avg
18.70%
Market Cap
$6.65M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.87M
Debt to Assets Ratio
0.54%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.94M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | $6.72M | 6.66% | 8.38% | 8.02% | 18.70% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.65M | 0.00% | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.60M | 0.00% | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.54M | 0.28% | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $6.82M | 0.00% | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.87M | 0.54% | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | 0.11% | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $6.96M | 0.00% | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.28M | 0.39% | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.00M | 0.05% | N/A | N/A | N/A |
Debt/Assets
6.7%
Debt/Equity
N/A
Current Ratio
0.70
Interest Coverage
-545.7x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 6.66% |
| 2026-03-31 | 11.34% |
| 2025-12-31 | 4.12% |
| 2025-09-30 | 12.19% |
| 2025-06-30 | 7.62% |
| 2025-03-31 | 5.58% |
| 2024-12-31 | 5.39% |
| 2024-09-30 | 4.13% |
| 2024-06-30 | 16.26% |
| 2024-03-31 | 4.85% |
| 2023-12-31 | 31.56% |
| 2023-09-30 | 10.99% |
| 2023-06-30 | 7.18% |
| 2023-03-31 | 0.49% |
| 2022-12-31 | 75.34% |
| 2022-09-30 | 108.27% |
| 2022-06-30 | 33.55% |
| 2022-03-31 | 62.06% |
| 2021-12-31 | 104.85% |
| 2021-09-30 | 50.87% |
| 2021-06-30 | 5.18% |
| 2021-03-31 | 412.25% |
| 2020-12-31 | 1213.90% |
| 2020-09-30 | 4.26% |
| 2020-06-30 | 4.22% |
| 2020-03-31 | 2.54% |
| 2019-12-31 | 0.29% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 93.75% |
